Illumina Inc

Stock Chart, Company Information, and Scan Results

$184.68(as of Jul 20, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Illumina Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$184.68
Ticker SymbolILMN
ExchangeNasdaq
SectorHealthcare
IndustryDiagnostics & Research
Employees8,600
CountyUSA
Market Cap$28,240.1M
EBIDTA1,155.0M
10-Day Moving Average190.32
P/E Ratio33.70
20-Day Moving Average182.51
Forward P/E Ratio35.59
50-Day Moving Average165.00
Earnings per Share5.51
200-Day Moving Average134.85
Profit Margin12.28%
RSI58.35
Shares Outstanding151.3M
ATR6.82
52-Week High196.66
Volume1,251,200
52-Week Low88.00
Most Recent Support Level184.02
Book Value2,676.0M
Most Recent Resistance Level194.18
P/B Ratio10.74
Upper Keltner197.86
P/S Ratio6.55
Lower Keltner167.16
Debt-to-Equity Ratio0.95
Next Earnings Date07/30/2026
Cash Surplus-477.0M
Next Ex-Dividend DateUnknown

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.